ライフサイエンスコーパス: community-acquired pneumonia

1 s known to increase the risk and severity of community acquired pneumonia.

2 recognized as important etiologic agents in community acquired pneumonia.

3 of Asian patients admitted to hospital with community-acquired pneumonia.

4 ide therapy for critically ill patients with community-acquired pneumonia.

5 her regimens in critically ill patients with community-acquired pneumonia.

6 iae is the most common causative pathogen in community-acquired pneumonia.

7 factor (MIF) have been linked to the risk of community-acquired pneumonia.

8 e of hospitalization of patients affected by community-acquired pneumonia.

9 r amoxicillin for children hospitalized with community-acquired pneumonia.

10 al use of corticosteroids in severe cases of community-acquired pneumonia.

11 secutively collected patients diagnosed with community-acquired pneumonia.

12 uman nasopharynx and is the leading cause of community-acquired pneumonia.

13 ealthcare-associated pneumonia (HCAP) versus community-acquired pneumonia.

14 ptococcus pneumoniae is the leading cause of community-acquired pneumonia.

15 m monotherapy for children hospitalized with community-acquired pneumonia.

16 . the other for elderly patients with severe community-acquired pneumonia.

17 ung injury in African American children with community-acquired pneumonia.

18 iae is the most common causative organism in community-acquired pneumonia.

19 entilation in African American children with community-acquired pneumonia.

20 nd skin structure infection and hospitalized community-acquired pneumonia.

21 to compare these with the same parameters in community-acquired pneumonia.

22 -negative bacterium that causes 10 to 20% of community-acquired pneumonia.

23 ommonly isolated organism from patients with community-acquired pneumonia.

24 ated with increased inflammation and risk of community-acquired pneumonia.

25 F expression may have a beneficial effect in community-acquired pneumonia.

26 Mycoplasma pneumoniae is a leading cause of community-acquired pneumonia.

27 linical trial involving patients with severe community-acquired pneumonia.

28 merging as an important etiological agent of community-acquired pneumonia.

29 nfections causing sinusitis, bronchitis, and community-acquired pneumonia.

30 rity criteria in a clinical trial for severe community-acquired pneumonia.

31 respiratory failure and ARDS in adults with community-acquired pneumonia.

32 ed for mechanical ventilation in adults with community-acquired pneumonia.

33 accharide vaccine alters the overall risk of community-acquired pneumonia.

34 gnosed diabetes mellitus was prevalent among community-acquired pneumonia.

35 pneumococcal pneumonia among 149 adults with community-acquired pneumonia.

36 human pathogen and the most common cause of community-acquired pneumonia.

37 rm of acute to subacute antibiotic-resistant community-acquired pneumonia.

38 ed by fat embolism and infection, especially community-acquired pneumonia.

39 onfirm the efficacy of TMP-SMZ in preventing community-acquired pneumonia.

40 l pneumonia among hospitalized patients with community-acquired pneumonia.

41 lidated--for treating adult outpatients with community-acquired pneumonia.

42 cus pneumoniae is the most frequent cause of community-acquired pneumonia.

43 ged 1-59 months enrolled in a large study of community-acquired pneumonia.

44 story and physical examination in diagnosing community-acquired pneumonia.

45 rveillance study of adults hospitalized with community-acquired pneumonia.

46 ors for poor outcomes in adult patients with community-acquired pneumonia.

47 making analysis of Sepsis-3 in patients with community-acquired pneumonia.

48 ing acute respiratory disease (ARD), such as community-acquired pneumonia.

49 is the cornerstone of medical management for community-acquired pneumonia.

50 iae is the most common causative pathogen in community-acquired pneumonia.

51 ute respiratory distress syndrome induced by community-acquired pneumonia.

52 treatment of Asian patients with PORT III-IV community-acquired pneumonia.

53 ute respiratory distress syndrome induced by community-acquired pneumonia.

54 emic inflammatory response syndrome, 100 for community-acquired pneumonia, 112 for urinary tract infe

55 nrolled 402 adults > or = 18 yrs of age with community-acquired pneumonia; 158 were white, 243 were A

56 ics included healthcare-associated (53%) and community-acquired pneumonias (17%).

57 acute myocardial infarction (2.85 days) and community-acquired pneumonia (2.22 days).

58 , 1428 cohort members were hospitalized with community-acquired pneumonia, 3061 were assigned a diagn

59 Patients with nonbacteremic community-acquired pneumonia also were tested by these m

60 Incidence estimates of hospitalizations for community-acquired pneumonia among children in the Unite

61 The organism has been associated with community acquired pneumonia and acute exacerbation of c

62 ureus is a significant cause of hospital and community acquired pneumonia and causes secondary infect

63 is the most common organism responsible for community acquired pneumonia and meningitis.

64 nary sarcoidosis, pulmonary tuberculosis, to community acquired pneumonia and primary lung cancer and

65 ospitals involving patients with both severe community-acquired pneumonia and a high inflammatory res

66 eumoniae is the primary etiological agent of community-acquired pneumonia and a major cause of mening

67 gionella are recognised as a common cause of community-acquired pneumonia and a rare cause of hospita

68 ac complications are common in patients with community-acquired pneumonia and are associated with inc

69 We describe severe community-acquired pneumonia and bacteremia caused by He

70 o UK intensive care units with sepsis due to community-acquired pneumonia and evidence of organ dysfu

71 reptococcus pneumoniae is a leading cause of community-acquired pneumonia and gram-positive sepsis.

72 y helpful in the evaluation of patients with community-acquired pneumonia and has also been recommend

73 sma pneumoniae accounts for 20 to 30% of all community-acquired pneumonia and has been associated wit

74 Among patients with severe community-acquired pneumonia and high initial inflammato

75 ccal infection in epidemiological studies of community-acquired pneumonia and in vaccine efficacy tri

76 ntigen detection assay were used to identify community-acquired pneumonia and invasive pneumococcal d

77 Chlamydia pneumoniae causes community-acquired pneumonia and is associated with seve

78 e (the pneumococcus) is the leading cause of community-acquired pneumonia and is now recognized to be

79 It is recognized that community-acquired pneumonia and lung abscesses can be t

80 ptococcus pneumoniae is the leading cause of community-acquired pneumonia and nasal carriage is a pre

81 dividually and in combination, in diagnosing community-acquired pneumonia and predicting short-term r

82 ptococcus pneumoniae is the leading cause of community-acquired pneumonia and results in over 1 milli

83 udomonas pneumonia, and associations between community-acquired pneumonia and risks or outcomes have

84 ptococcus pneumoniae is the leading cause of community-acquired pneumonia and sepsis, with adult hosp

85 Streptococcus pneumoniaeis a major cause of community-acquired pneumonia and septicemia in adults.

86 ty of care for black vs. white patients with community-acquired pneumonia and suggested that disparit

87 on treatment in critically ill patients with community-acquired pneumonia and support current guideli

88 pneumococcal, bacteremic, and nonbacteremic community-acquired pneumonia and vaccine-type invasive p

89 oniae continues to be a significant cause of community-acquired pneumonia and, on rare occasions, man

90 infections, including tracheobronchitis and community acquired pneumonia, and is linked to asthma an

91 ax, 71.8% specific (64.8-78.1) compared with community-acquired pneumonia, and 95.6% specific (90.0-9

92 reptococcus pneumoniae, the leading cause of community-acquired pneumonia, and group B Streptococcus,

93 possibly spontaneous bacterial peritonitis, community-acquired pneumonia, and infection with Mycobac

94 , nonbacteremic and noninvasive pneumococcal community-acquired pneumonia, and invasive pneumococcal

95 during a lower respiratory tract infection, community-acquired pneumonia, and pneumonia associated w

96 In adults hospitalized with community-acquired pneumonia, antibiotic therapy consist

97 he guideline-concordant therapies for severe community-acquired pneumonia are either a beta-lactam an

98 them to a cohort of patients with bacterial community-acquired pneumonia (B-CAP).

99 ving extracorporeal membrane oxygenation for community-acquired pneumonia between 2002 and 2012.

100 re also detected in isolates responsible for community-acquired pneumonia, burn infections, bacteremi

101 e infections of humans are a common cause of community acquired pneumonia but have also been linked t

102 high level of certainty in the diagnosis of community-acquired pneumonia, but the absence of vital s

103 ociated with a poor outcome in patients with community acquired pneumonia (CAP).

104 Mycoplasma pneumoniae is a leading cause of community-acquired pneumonia (CAP) across patient popula

105 Community-acquired pneumonia (CAP) affects >5 million ad

106 , 5, 7F, and 19A were the most implicated in community-acquired pneumonia (CAP) after implementation

107 linical effectiveness of PPV23 in preventing community-acquired pneumonia (CAP) among the general pop

108 en aged <18 years who were hospitalized with community-acquired pneumonia (CAP) and children asymptom

109 neumoniae causes a substantial proportion of community-acquired pneumonia (CAP) and healthcare-associ

110 Prevalence of Staphylococcus aureus community-acquired pneumonia (CAP) and its clinical feat

111 om a previously healthy 26-year-old man with community-acquired pneumonia (CAP) and multiple brain ab

112 , rs1800451, and rs7096206) in 1839 European community-acquired pneumonia (CAP) and peritonitis sepsi

113 Community-acquired pneumonia (CAP) and sepsis are import

114 ent pneumonia following hospitalization with community-acquired pneumonia (CAP) are poorly understood

115 Recent case series describe severe community-acquired pneumonia (CAP) caused by MRSA, but t

116 Clinical decision making relative to community-acquired pneumonia (CAP) diagnosis is difficul

117 ggest that statins may benefit patients with community-acquired pneumonia (CAP) due to antiinflammato

118 availability, but hospitalized patients with community-acquired pneumonia (CAP) generally are treated

119 Initial management of community-acquired pneumonia (CAP) has been a Centers fo

120 ng proton pump inhibitor (PPI) exposure with community-acquired pneumonia (CAP) have reported either

121 In a post hoc analysis of the Community-Acquired Pneumonia (CAP) immunization Trial in

122 quent lack of a microbiological diagnosis in community-acquired pneumonia (CAP) impairs pathogen-dire

123 Inhaled corticosteroids (ICS) increase community-acquired pneumonia (CAP) incidence in patients

124 Community-acquired pneumonia (CAP) is a frequent cause o

125 Community-acquired pneumonia (CAP) is a leading cause of

126 Previous reports suggest that community-acquired pneumonia (CAP) is associated with an

127 Community-acquired pneumonia (CAP) is common and often s

128 Understanding the burden of community-acquired pneumonia (CAP) is critical to alloca

129 if sex-related survival difference following community-acquired pneumonia (CAP) is due to differences

130 Information on the long-term prognosis after community-acquired pneumonia (CAP) is limited.

131 ficance of viruses detected in patients with community-acquired pneumonia (CAP) is often unclear.

132 Community-acquired pneumonia (CAP) is the major manifest

133 Community-acquired pneumonia (CAP) remains one of the mo

134 The effect of body mass index (BMI) on community-acquired pneumonia (CAP) severity is unclear.

135 important features and management issues of community-acquired pneumonia (CAP) that are especially r

136 ity and a parallel inception cohort study of community-acquired pneumonia (CAP) to assess risk of sev

137 In a prospective study, the etiology of community-acquired pneumonia (CAP) was investigated amon

138 tment for patients with clinically suspected community-acquired pneumonia (CAP) who are admitted to n

139 l evaluation of changes in hospital care for community-acquired pneumonia (CAP), little is known abou

140 e plasma HMGB1 concentrations in humans with community-acquired pneumonia (CAP), the most common caus

141 ons with HCAP compared with populations with community-acquired pneumonia (CAP).

142 tive assay for the diagnosis of pneumococcal community-acquired pneumonia (CAP).

143 a second-line regimen for some patients with community-acquired pneumonia (CAP).

144 the impact of vitamin D status on outcome in community-acquired pneumonia (CAP).

145 d mortality among patients hospitalized with community-acquired pneumonia (CAP).

146 has been implicated in the etiology of adult community-acquired pneumonia (CAP).

147 ostic indicator in persons hospitalized with community-acquired pneumonia (CAP).

148 inhibitors (PPIs) may increase the risk for community-acquired pneumonia (CAP).

149 eptococcus pneumoniae in adult patients with community-acquired pneumonia (CAP).

150 gen detection for patients hospitalized with community-acquired pneumonia (CAP).

151 ureus (7%) were the predominant pathogens in community-acquired pneumonia (CAP).

152 hospitalized adult patients with multilobar community-acquired pneumonia (CAP).

153 c pathogen in more than 50% of patients with community-acquired pneumonia (CAP).

154 nd management of immunocompetent adults with community-acquired pneumonia (CAP).

155 used previously to determine the etiology of community-acquired pneumonia (CAP).

156 -acquired pneumonia (HAP) when compared with community-acquired pneumonia (CAP).

157 g cause of respiratory infections, including community-acquired pneumonia (CAP).

158 dy of 445 pneumonia patients, including both community-acquired pneumonia (CAP; n = 124) and HCAP (n

159 gnosed diabetes mellitus in a large European community-acquired pneumonia cohort.

160 ty-acquired pneumonia included in the German Community-Acquired Pneumonia Competence Network (CAPNETZ

161 al multicenter study of hospitalizations for community-acquired pneumonia conducted from January 2010

162 hage, trauma, acute renal failure, or severe community-acquired pneumonia did not differ statisticall

163 11 hospitals in West Midlands, England, with community-acquired pneumonia during 1996-1999 were inter

164 nary samples from 196 Tunisian patients with community-acquired pneumonia during the period 2009-2010

165 e pneumococcal disease but not in preventing community-acquired pneumonia from any cause.

166 a cohort study including adult patients with community-acquired pneumonia from two Spanish university

167 erican Thoracic Society definition of severe community-acquired pneumonia had high specificity but lo

168 antibiotics within 4 hours to patients with community-acquired pneumonia has been criticized as a qu

169 IPD and the most resource-intensive type of community-acquired pneumonia, hospital-treated pneumonia

170 nter, prospective, population-based study of community-acquired pneumonia hospitalizations conducted

171 developed to predict the 30 day mortality in community acquired pneumonia; however, several guideline

172 In the randomized controlled Community-Acquired Pneumonia Immunization Trial in Adult

173 g et al. proposed a new definition of severe community-acquired pneumonia in 1999, which was adopted

174 whether hantaviruses contributed to cases of community-acquired pneumonia in a large Baltimore hospit

175 nts, but their efficacy against pneumococcal community-acquired pneumonia in adults 65 years of age o

176 CV13) against first episodes of vaccine-type community-acquired pneumonia in adults aged >/=65 years

177 Data on outcomes from severe community-acquired pneumonia in adults receiving rescue

178 Coccidioidomycosis is a common cause of community-acquired pneumonia in areas of the southwester

179 Child Health (PERCH) study, a large study of community-acquired pneumonia in children aged 1-59 month

180 ination is associated with a reduced risk of community-acquired pneumonia in immunocompetent elderly

181 safe in pregnancy and are effective for most community-acquired pneumonia in pregnancy.

182 olipid lysoPCaC26:1 identified patients with community-acquired pneumonia in sepsis or severe sepsis/

183 butes to the pathogenesis of childhood acute community-acquired pneumonia in settings with a high tub

184 Thus, hantaviruses are an uncommon cause of community-acquired pneumonia in the Baltimore area.

185 e analyses of risk and prognostic factors in community-acquired pneumonia in the elderly have found t

186 usefulness as prompt tools for patients with community-acquired pneumonia in the emergency department

187 y-seven patients met the criteria for severe community-acquired pneumonia in the emergency department

188 oninstitutionalized adults hospitalized with community-acquired pneumonia in two Ohio counties were e

189 dromes (including bloodstream infections and community-acquired pneumonia) in children and neonates (

190 o preventing pneumococcal disease, including community-acquired pneumonia, in adults.

191 in rates of hospitalization of patients with community-acquired pneumonia, in part because of physici

192 ny and Austria encompassing 1961 adults with community-acquired pneumonia included in the German Comm

193 iency virus (HIV) infection hospitalized for community-acquired pneumonia, including Pneumocystis car

194 1 are associated with unfavorable outcome in community-acquired pneumonia, intra-abdominal infections

195 Community-acquired pneumonia is a leading infectious cau

196 Community-acquired pneumonia is an important cause of ac

197 e severe lung injury in children who develop community-acquired pneumonia is associated with variatio

198 l management of patients suspected of having community-acquired pneumonia is challenging because of t

199 Community-acquired pneumonia is commonly caused by Strep

200 Diagnosing community-acquired pneumonia is complex, and a diagnosti

201 Once community-acquired pneumonia is diagnosed, a combination

202 es mellitus and prediabetes in patients with community-acquired pneumonia is largely unknown.

203 In many patients, the etiology of community-acquired pneumonia is not known but may be cau

204 Community-acquired pneumonia is the most common form of

205 ococcus pneumoniae, the most common cause of community-acquired pneumonia, is increasing in the Unite

206 orticoids in the management of patients with community-acquired pneumonia, liver failure, pancreatiti

207 f almost 10,000 critically ill patients with community-acquired pneumonia, macrolide use was associat

208 sepsis due to fecal peritonitis (n = 117) or community-acquired pneumonia (n = 126), and of control s

209 ute respiratory distress syndrome induced by community-acquired pneumonia (n=10), CXCR1 and CXCR2 exp

210 odes of vaccine-type strains of pneumococcal community-acquired pneumonia, nonbacteremic and noninvas

211 21.8 to 62.5), nonbacteremic and noninvasive community-acquired pneumonia occurred in 33 persons in t

212 s of infections due to vaccine-type strains, community-acquired pneumonia occurred in 49 persons in t

213 37.7%, 41.1%, and 75.8%, respectively), and community-acquired pneumonia occurred in 747 persons in

214 on was not associated with a reduced risk of community-acquired pneumonia (odds ratio 0.92, 95% CI 0.

215 nhalational anthrax cases than in either the community-acquired pneumonia or influenza-like illness c

216 rism-related anthrax) with 376 controls with community-acquired pneumonia or influenza-like illness.

217 f recombinant TFPI to treat severe sepsis in community-acquired pneumonia or to achieve improved engr

218 88; n = 921 participants), and S. pneumoniae community-acquired pneumonia (OR = 2.15; 95% CI = 1.32-3

219 est differences in circulating biomarkers in community-acquired pneumonia, perhaps as a result of hea

220 Postobstructive community-acquired pneumonia (PO-CAP) is relatively comm

221 hospitalized with radiographically confirmed community-acquired pneumonia published from January 1, 1

222 is a recommended treatment for patients with community-acquired pneumonia requiring hospital admissio

223 ted active population-based surveillance for community-acquired pneumonia requiring hospitalization a

224 lculated population-based incidence rates of community-acquired pneumonia requiring hospitalization a

225 ted active population-based surveillance for community-acquired pneumonia requiring hospitalization a

226 The incidence of community-acquired pneumonia requiring hospitalization w

227 iae is the most common causative organism in community-acquired pneumonia responsible for millions of

228 DSA/ATS 2007) criteria for predicting severe community-acquired pneumonia (SCAP) and evaluate a healt

229 f viral infections in the etiology of severe community-acquired pneumonia (SCAP) was prospectively ev

230 overgrowth, enteric infection, and possibly community-acquired pneumonia, spontaneous bacterial peri

231 As the leading cause of community-acquired pneumonia, Streptococcus pneumoniae w

232 The majority (66%) of adults with community-acquired pneumonia supported on extracorporeal

233 common virus was primarily associated with a community-acquired pneumonia syndrome and caused substan

234 a pathogenic bacterium and a major cause of community-acquired pneumonia that could be fatal if left

235 iratory failure as a consequence of a severe community-acquired pneumonia that required central venou

236 cardiac complications occur in patients with community-acquired pneumonia, their incidence, timing, r

237 Among children and adults hospitalized with community-acquired pneumonia, those with laboratory-conf

238 ts) and patients admitted with sepsis due to community-acquired pneumonia to 29 ICUs in the UK (secon

239 pneumoniae is a major causative pathogen in community-acquired pneumonia; together with influenza vi

240 In patients with severe community-acquired pneumonia, treatment failure is assoc

241 In 77 patients with nonbacteremic community-acquired pneumonia, urinary antigen was detect

242 4.7%, 78.2%, 75%, and 87%, respectively, for community-acquired pneumonia validated against a blinded

243 ary outcomes were hospitalization because of community-acquired pneumonia (validated by chart review)

244 s with an episode of outpatient or inpatient community-acquired pneumonia (validated by review of med

245 burden of hospitalization for children with community-acquired pneumonia was highest among the very

246 ysis of data on 14,199 adult inpatients with community-acquired pneumonia, we derived a prediction ru

247 of 1343 inpatients and 944 outpatients with community-acquired pneumonia were followed up prospectiv

248 Research Team (PORT) risk class III-IV acute community-acquired pneumonia were randomly assigned (1:1

249 not be optimal as a first-line treatment for community-acquired pneumonia when it follows influenza.

250 tes mellitus is an important risk factor for community-acquired pneumonia, whereas the prevalence of

251 ce interval, 0.96 to 1.13) or of any case of community-acquired pneumonia, whether or not it required

252 o penicillin and macrolides in many cases of community acquired pneumonia, which has resulted in shif

253 ribe accurately identifies the patients with community-acquired pneumonia who are at low risk for dea

254 of 278 consecutive patients hospitalized for community-acquired pneumonia, who were followed up until

255 ptococcus pneumoniae is the leading cause of community-acquired pneumonia worldwide, resulting in hig

256 occus pneumoniae is the most common cause of community-acquired pneumonia worldwide.